{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T07:35:20Z","timestamp":1769931320669,"version":"3.49.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2001,1,1]]},"DOI":"10.1038\/sj.leu.2401994","type":"journal-article","created":{"date-parts":[[2002,9,4]],"date-time":"2002-09-04T18:38:21Z","timestamp":1031164701000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies"],"prefix":"10.1038","volume":"15","author":[{"given":"AM","family":"Senderowicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2001,1,23]]},"reference":[{"key":"BF2401994_CR1","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","volume":"274","author":"CJ Sherr","year":"1996","unstructured":"Sherr CJ . Cancer cell cycles Science 1996 274: 1672\u20131677","journal-title":"Science"},{"key":"BF2401994_CR2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0092-8674(00)80714-X","volume":"97","author":"HS Zhang","year":"1999","unstructured":"Zhang HS, Postigo AA, Dean DC . Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition Cell 1999 97: 53\u201361","journal-title":"Cell"},{"key":"BF2401994_CR3","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1101\/gad.12.15.2245","volume":"12","author":"N Dyson","year":"1998","unstructured":"Dyson N . The regulation of E2F by pRB-family proteins Genes Dev 1998 12: 2245\u20132262","journal-title":"Genes Dev"},{"key":"BF2401994_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-1-4615-1809-9_2","volume":"1","author":"M Hatakeyama","year":"1995","unstructured":"Hatakeyama M, Weinberg RA . The role of RB in cell cycle control Prog Cell Cycle Res 1995 1: 9\u201319","journal-title":"Prog Cell Cycle Res"},{"key":"BF2401994_CR5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(95)90385-2","volume":"81","author":"RA Weinberg","year":"1995","unstructured":"Weinberg RA . The retinoblastoma protein and cell cycle control Cell 1995 81: 323\u2013330","journal-title":"Cell"},{"key":"BF2401994_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.cellbio.13.1.261","volume":"13","author":"DO Morgan","year":"1997","unstructured":"Morgan DO . Cyclin-dependent kinases: engines, clocks, and microprocessors Annu Rev Cell Dev Biol 1997 13: 261\u2013291","journal-title":"Annu Rev Cell Dev Biol"},{"key":"BF2401994_CR7","first-page":"2631","volume":"12","author":"P Rickert","year":"1996","unstructured":"Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E . Cyclin C\/CDK8 is a novel CTD kinase associated with RNA polymerase II Oncogene 1996 12: 2631\u20132640","journal-title":"Oncogene"},{"key":"BF2401994_CR8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0092-8674(00)80939-3","volume":"92","author":"P Wei","year":"1998","unstructured":"Wei P, Garber ME, Fang SM, Fischer WH, Jones KA . A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA Cell 1998 92: 451\u2013462","journal-title":"Cell"},{"key":"BF2401994_CR9","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1073\/pnas.91.9.3834","volume":"91","author":"X Grana","year":"1994","unstructured":"Grana X, De Luca A, Sang N, Fu Y, Claudio PP, Rosenblatt J, Morgan DO, Giordano A . PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro Proc Natl Acad Sci USA 1994 91: 3834\u20133838","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2401994_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1615\/CritRevEukarGeneExpr.v5.i2.20","volume":"5","author":"TK MacLachlan","year":"1995","unstructured":"MacLachlan TK, Sang N, Giordano A . Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer Crit Rev Eukaryot Gene Expr 1995 5: 127\u2013156","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"BF2401994_CR11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1101\/gad.12.5.755","volume":"12","author":"J Peng","year":"1998","unstructured":"Peng J, Zhu Y, Milton JT, Price DH . Identification of multiple cyclin subunits of human P-TEFb Genes Dev 1998 12: 755\u2013762","journal-title":"Genes Dev"},{"key":"BF2401994_CR12","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","volume":"13","author":"CJ Sherr","year":"1999","unstructured":"Sherr CJ, Roberts JM . CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev 1999 13: 1501\u20131512","journal-title":"Genes Dev"},{"key":"BF2401994_CR13","first-page":"211","volume":"11","author":"X Grana","year":"1995","unstructured":"Grana X, Reddy EP . Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs) Oncogene 1995 11: 211\u2013219","journal-title":"Oncogene"},{"key":"BF2401994_CR14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-230X(08)60254-7","volume":"66","author":"J Pines","year":"1995","unstructured":"Pines J . Cyclins and cyclin-dependent kinases: theme and variations Adv Cancer Res 1995 66: 181\u2013212","journal-title":"Adv Cancer Res"},{"key":"BF2401994_CR15","first-page":"4608","volume":"57","author":"MH Dreyling","year":"1997","unstructured":"Dreyling MH, Bullinger L, Ott G, Stilgenbauer S, Muller-Hermelink HK, Bentz M, Hiddemann W, Dohner H . Alterations of the cyclin D1\/p16-pRB pathway in mantle cell lymphoma Cancer Res 1997 57: 4608\u20134614","journal-title":"Cancer Res"},{"key":"BF2401994_CR16","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood.V90.8.3154","volume":"90","author":"MM Ott","year":"1997","unstructured":"Ott MM, Bartkova J, Bartek J, Durr A, Fischer L, Ott G, Muller-Hermelink HK, Kreipe H . Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity Blood 1997 90: 3154\u20133159","journal-title":"Blood"},{"key":"BF2401994_CR17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.leu.2400581","volume":"11","author":"A Alessandrini","year":"1997","unstructured":"Alessandrini A, Chiaur DS, Pagano M . Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation Leukemia 1997 11: 342\u2013345","journal-title":"Leukemia"},{"key":"BF2401994_CR18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3109\/10428199609054859","volume":"23","author":"R Siebert","year":"1996","unstructured":"Siebert R, Willers CP, Opalka B . Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma Leuk Lymphoma 1996 23: 505\u2013520","journal-title":"Leuk Lymphoma"},{"key":"BF2401994_CR19","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1182\/blood.V89.8.2938","volume":"89","author":"G Bergh","year":"1997","unstructured":"Bergh G, Ehinger M, Olofsson T, Baldetorp B, Johnsson E, Brycke H, Lindgren G, Olsson I, Gullberg U . Altered expression of the retinoblastoma tumor-suppressor gene in leukemic cell lines inhibits induction of differentiation but not G1-accumulation Blood 1997 89: 2938\u20132950","journal-title":"Blood"},{"key":"BF2401994_CR20","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1128\/MCB.18.6.3620","volume":"18","author":"C Neuveut","year":"1998","unstructured":"Neuveut C, Low KG, Maldarelli F, Schmitt I, Majone F, Grassmann R, Jeang KT . Human T-cell leukemia virus type 1 Tax and cell cycle progression: role of cyclin D-cdk and p110Rb Mol Cell Biol 1998 18: 3620\u20133632","journal-title":"Mol Cell Biol"},{"key":"BF2401994_CR21","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/elps.1150191119","volume":"19","author":"SM Hanash","year":"1998","unstructured":"Hanash SM, Teichroew D . Mining the human proteome: experience with the human lymphoid protein database Electrophoresis 1998 19: 2004\u20132009","journal-title":"Electrophoresis"},{"key":"BF2401994_CR22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev.med.50.1.401","volume":"50","author":"J Tsihlias","year":"1999","unstructured":"Tsihlias J, Kapusta L, Slingerland J . The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer Annu Rev Med 1999 50: 401\u2013423","journal-title":"Annu Rev Med"},{"key":"BF2401994_CR23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/92.5.376","volume":"92","author":"AM Senderowicz","year":"2000","unstructured":"Senderowicz AM, Sausville EA . Preclinical and clinical development of cyclin-dependent kinase modulators J Natl Cancer Inst 2000 92: 376\u2013387","journal-title":"J Natl Cancer Inst"},{"key":"BF2401994_CR24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1749-6632.2000.tb06710.x","volume":"910","author":"EA Sausville","year":"2000","unstructured":"Sausville EA, Johnson J, Alley M, Zaharevitz D, Senderowicz AM . Inhibition of CDKs as a therapeutic modality (in process citation) Ann NY Acad Sci 2000 910: 207\u2013221; discussion 221\u2013222","journal-title":"Ann NY Acad Sci"},{"key":"BF2401994_CR25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0163-7258(98)00062-X","volume":"82","author":"EA Sausville","year":"1999","unstructured":"Sausville EA, Zaharevitz D, Gussio R, Meijer L, Louarn-Leost M, Kunick C, Schultz R, Lahusen T, Headlee D, Stinson S, Arbuck SG, Senderowicz A . Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target (in process citation) Pharmacol Ther 1999 82: 285\u2013292","journal-title":"Pharmacol Ther"},{"key":"BF2401994_CR26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0076-6879(97)83011-X","volume":"283","author":"L Meijer","year":"1997","unstructured":"Meijer L, Kim SH . Chemical inhibitors of cyclin-dependent kinases Meth Enzymol 1997 283: 113\u2013128","journal-title":"Meth Enzymol"},{"key":"BF2401994_CR27","first-page":"2566","volume":"59","author":"DW Zaharevitz","year":"1999","unstructured":"Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, Sausville EA . Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases (in process citation) Cancer Res 1999 59: 2566\u20132569","journal-title":"Cancer Res"},{"key":"BF2401994_CR28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","volume":"243","author":"WF De Azevedo","year":"1997","unstructured":"De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH . Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine Eur J Biochem 1997 243: 518\u2013526","journal-title":"Eur J Biochem"},{"key":"BF2401994_CR29","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/jnci\/84.22.1736","volume":"84","author":"G Kaur","year":"1992","unstructured":"Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E . Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86\u20138275 J Natl Cancer Inst 1992 84: 1736\u20131740","journal-title":"J Natl Cancer Inst"},{"key":"BF2401994_CR30","first-page":"2973","volume":"56","author":"BA Carlson","year":"1996","unstructured":"Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ . Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells Cancer Res 1996 56: 2973\u20132978","journal-title":"Cancer Res"},{"key":"BF2401994_CR31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1006\/bbrc.1994.1742","volume":"201","author":"MD Losiewicz","year":"1994","unstructured":"Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ . Potent inhibition of CDC2 kinase activity by the flavonoid L86\u20138275 Biochem Biophys Res Commun 1994 201: 589\u2013595","journal-title":"Biochem Biophys Res Commun"},{"key":"BF2401994_CR32","first-page":"424","volume":"32","author":"B Carlson","year":"1996","unstructured":"Carlson B, Pearlstein R, Naik R, Sedlacek H, Sausville E, Worland P . Inhibition of CDK2, CDK4 and CDK7 by flavopiridol and structural analogs Proc Am Assoc Cancer Res 1996 32: 424","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF2401994_CR33","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/0006-2952(93)90590-S","volume":"46","author":"PJ Worland","year":"1993","unstructured":"Worland PJ, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville EA . Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86\u20138275 in breast carcinoma cells. Correlation with decreased H1 kinase activity Biochem Pharmacol 1993 46: 1831\u20131840","journal-title":"Biochem Pharmacol"},{"key":"BF2401994_CR34","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1073\/pnas.93.7.2735","volume":"93","author":"Jr De Azevedo WF","year":"1996","unstructured":"De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH . Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase Proc Natl Acad Sci USA 1996 93: 2735\u20132740","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2401994_CR35","first-page":"975","volume":"55","author":"R Michalides","year":"1995","unstructured":"Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A . Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck Cancer Res 1995 55: 975\u2013978","journal-title":"Cancer Res"},{"key":"BF2401994_CR36","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.1073\/pnas.94.12.6380","volume":"94","author":"S Fredersdorf","year":"1997","unstructured":"Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X . High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers Proc Natl Acad Sci USA 1997 94: 6380\u20136385","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2401994_CR37","first-page":"4634","volume":"59","author":"B Carlson","year":"1999","unstructured":"Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM . Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol Cancer Res 1999 59: 4634\u20134641","journal-title":"Cancer Res"},{"key":"BF2401994_CR38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.281.5376.533","volume":"281","author":"NS Gray","year":"1998","unstructured":"Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG . Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 1998 281: 533\u2013538","journal-title":"Science"},{"key":"BF2401994_CR39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/(SICI)1097-0215(19980703)77:1<146::AID-IJC22>3.0.CO;2-B","volume":"77","author":"S Brusselbach","year":"1998","unstructured":"Brusselbach S, Nettelbeck DM, Sedlacek HH, Muller R . Cell cycle-independent induction of apoptosis by the anti-tumor drug Flavopiridol in endothelial cells Int J Cancer 1998 77: 146\u2013152","journal-title":"Int J Cancer"},{"key":"BF2401994_CR40","first-page":"959","volume":"19","author":"JS Kerr","year":"1999","unstructured":"Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak A Jr, Slee AM . Novel small molecule alpha v integrin antagonists: comparative anti- cancer efficacy with known angiogenesis inhibitors (in process citation) Anticancer Res 1999 19: 959\u2013968","journal-title":"Anticancer Res"},{"key":"BF2401994_CR41","first-page":"5433","volume":"59","author":"G Melillo","year":"1999","unstructured":"Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM . Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes Cancer Res 1999 59: 5433\u20135437","journal-title":"Cancer Res"},{"key":"BF2401994_CR42","first-page":"161","volume":"15","author":"HR Lee","year":"1999","unstructured":"Lee HR, Chang TH, Tebalt MJ 3rd, Senderowicz AM, Szabo E . Induction of differentiation accompanies inhibition of cdk2 in a non-small cell lung cancer cell line (in process citation) Int J Oncol 1999 15: 161\u2013166","journal-title":"Int J Oncol"},{"key":"BF2401994_CR43","doi-asserted-by":"crossref","first-page":"28345","DOI":"10.1074\/jbc.C000446200","volume":"275","author":"SH Chao","year":"2000","unstructured":"Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH . Flavopiridol inhibits P-TEFb and blocks HIV-1 replication J Biol Chem 2000 275: 28345\u201328348","journal-title":"J Biol Chem"},{"key":"BF2401994_CR44","first-page":"1467","volume":"3","author":"G Schwartz","year":"1997","unstructured":"Schwartz G, Farsi K, Maslak P, Kelsen D, Spriggs D . Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells Clin Cancer Res 1997 3: 1467\u20131472","journal-title":"Clin Cancer Res"},{"key":"BF2401994_CR45","first-page":"3375","volume":"57","author":"KC Bible","year":"1997","unstructured":"Bible KC, Kaufmann SH . Cytotoxic synergy between flavopiridol (NSC 649890, L86\u20138275) and various antineoplastic agents: the importance of sequence of administration Cancer Res 1997 57: 3375\u20133380","journal-title":"Cancer Res"},{"key":"BF2401994_CR46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s002800050948","volume":"44","author":"M Chien","year":"1999","unstructured":"Chien M, Astumian M, Liebowitz D, Rinker-Schaeffer C, Stadler W . In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer Cancer Chemother Pharmacol 1999 44: 81\u201387","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2401994_CR47","first-page":"2482","volume":"91","author":"F Arguello","year":"1998","unstructured":"Arguello F, Alexander M, Sterry J, Tudor G, Smith E, Kalavar N, Greene J, Koss W, Morgan D, Stinson S, Siford T, Alvord W, Labansky R, Sausville E . Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppresion, and has potent antitumor activity in vivo against human and leukemia xenografts Blood 1998 91: 2482\u20132490","journal-title":"Blood"},{"key":"BF2401994_CR48","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804.422k36_3804_3816","volume":"92","author":"JC Byrd","year":"1998","unstructured":"Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E, Grever MR . Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 Blood 1998 92: 3804\u20133816","journal-title":"Blood"},{"key":"BF2401994_CR49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood.V91.2.458","volume":"91","author":"B Parker","year":"1998","unstructured":"Parker B, Nieves-Neira W, Taimi M, Kolhagen G, Shimizu T, Pommier Y, Sausville E, Senderowicz AM . Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol Blood 1998 91: 458\u2013465","journal-title":"Blood"},{"key":"BF2401994_CR50","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1182\/blood.V90.11.4307","volume":"90","author":"A Konig","year":"1997","unstructured":"Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL . The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines Blood 1997 90: 4307\u20134312","journal-title":"Blood"},{"key":"BF2401994_CR51","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V96.2.393","volume":"96","author":"S Kitada","year":"2000","unstructured":"Kitada S, Zapata JM, Andreeff M, Reed JC . Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia (in process citation) Blood 2000 96: 393\u2013397","journal-title":"Blood"},{"key":"BF2401994_CR52","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/sj.leu.2400555","volume":"11","author":"DM Jadayel","year":"1997","unstructured":"Jadayel DM, Lukas J, Nacheva E, Bartkova J, Stranks G, De Schouwer PJ, Lens D, Bartek J, Dyer MJ, Kruger AR, Catovsky D . Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519) Leukemia 1997 11: 64\u201372","journal-title":"Leukemia"},{"key":"BF2401994_CR53","unstructured":"Guedez L, Quintanilla-Martinez L, Lahusen T, Davies T, Singh SS, Barotto N, Vistica D, Raffeld M, Sausville EA, Senderowicz AM . Flavopiridol-induced apoptosis is associated with a decrease in Cyclin D1 in mantle lymphoma cell lines. Proc Ninetieth Annual Meeting of the American Association of Cancer Research, Philadelphia, PA, 1999"},{"key":"BF2401994_CR54","first-page":"1018, 1023","volume":"12","author":"J Wright","year":"1998","unstructured":"Wright J, Blatner GL, Cheson BD . Clinical trials referral resource. Clinical trials of flavopiridol Oncology 1998 12: 1018, 1023\u20131024","journal-title":"Oncology"},{"key":"BF2401994_CR55","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1172\/JCI3661","volume":"102","author":"V Patel","year":"1998","unstructured":"Patel V, Senderowicz AM, Pinto D, Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS . Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis J Clin Invest 1998 102: 1674\u20131681","journal-title":"J Clin Invest"},{"key":"BF2401994_CR56","unstructured":"Lahusen J, Loaiza-Perez A, Sausville EA, Senderowicz AM . Flavopiridol-induced apoptosis is associated with p38 and MEK activation and is prevented by caspase and MAPK inhibitors Proc Twentieth Annual Meeting of the American Association of Cancer Research, San Francisco, CA, 2000"},{"key":"BF2401994_CR57","doi-asserted-by":"crossref","first-page":"32089","DOI":"10.1074\/jbc.M005267200","volume":"275","author":"T Achenbach","year":"2000","unstructured":"Achenbach T, Muller R, Slater EP . Bcl-2 independence of flavopiridol-induced apoptosis: mitochondrial depolarization in the absence of cytochrome c release J Biol Chem 2000 275: 32089\u201332097","journal-title":"J Biol Chem"},{"key":"BF2401994_CR58","first-page":"1143","volume":"9","author":"HH Sedlacek","year":"1996","unstructured":"Sedlacek HH, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E . Flavopiridol (L86\u20138275, NSC-649890), a new kinase inhibitor for tumor therapy Int J Oncol 1996 9: 1143\u20131168","journal-title":"Int J Oncol"},{"key":"BF2401994_CR59","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1200\/JCO.1998.16.9.2986","volume":"16","author":"AM Senderowicz","year":"1998","unstructured":"Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA . Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms J Clin Oncol 1998 16: 2986\u20132999","journal-title":"J Clin Oncol"},{"key":"BF2401994_CR60","unstructured":"Thomas J, Cleary J, Tutsch K, Arzoomanian R, Alberti D, Simon K, Feierabend D, Morgan K, Wilding G . Phase I clinical and pharmacokinetic trial of flavopiridol Proc. Eighty-eightieth Annual Meeting of the American Association of Cancer Research, San Diego, CA 1997"},{"key":"BF2401994_CR61","unstructured":"Senderowicz AM, Messmann R, Arbuck S, Headlee D, Zhai S, Murgo A, Melillo G, Figg W, Sausville E . A Phase I trial of 1 hour infusion of flavopiridol (Fla), a novel cyclin-dependent kinase inhibitor, in patients with advanced neoplasms. Proc Annual Meeting of the American Society of Clinical Oncology, New Orleans, 2000"},{"key":"BF2401994_CR62","unstructured":"Schwartz G, Kaubisch A, Saltz L, Ilson D, O'Reilly E, Barazzuol J, Endres S, Soltz M, Tong W, Spriggs D, Kelsen D . Phase I trial of sequential paclitaxel and the cyclin-dependent kinase inhibitor flavopiridol Proceedings of the American Society of Clinical Oncology, Atlanta, GA, 1999 p 160"},{"key":"BF2401994_CR63","unstructured":"Werner J, Kelsen D, Karpeh M, Inzeo D, Barazzuol J, Sugarman A, SchwartzGK . The cyclin-dependent kinase inhibitor flavopiridol is an active and unexpectedly toxic agent in advanced gastric cancer Proceedings of the American Society of Clinical Oncology, Los Angeles, CA, 1998"},{"key":"BF2401994_CR64","unstructured":"Shapiro G, Patterson A, Lynch C, Lucca J, Anderson I, Boral A, Elias A, Lu H, Salgia R, Skarin A, Panek-Clark C, McKenna R, Rabin M, Vasconcelles M, Eder P, Supko J, Lynch T, Rollins B . A phase II trial of flavopiridol in patients with stage IV non-small cell lung cancer Proceedings of the American Society of Clinical Oncology, Atlanta, GA, 1999"},{"key":"BF2401994_CR65","unstructured":"Bennett S, Mani S, O'Reilly S, Wright J, Schilsky R, Vokes E, Grochow L . Phase II trial of flavopiridol in metastatic colorectal cancer: preliminary results Proceedings of the American Society of Clinical Oncology, Atlanta, GA, 1999"},{"key":"BF2401994_CR66","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.2000.18.2.371","volume":"18","author":"WM Stadler","year":"2000","unstructured":"Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE . Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago phase II Consortium study J Clin Oncol 2000 18: 371\u2013375","journal-title":"J Clin Oncol"},{"key":"BF2401994_CR67","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/0076-6879(91)01030-6","volume":"201","author":"T Tamaoki","year":"1991","unstructured":"Tamaoki T . Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors Meth Enzymol 1991 201: 340\u2013347","journal-title":"Meth Enzymol"},{"key":"BF2401994_CR68","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.7164\/antibiotics.40.1782","volume":"40","author":"I Takahashi","year":"1987","unstructured":"Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H . UCN-01, a selective inhibitor of protein kinase C from Streptomyces J Antibiot 1987 40: 1782\u20131784","journal-title":"J Antibiot"},{"key":"BF2401994_CR69","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7164\/antibiotics.42.571","volume":"42","author":"I Takahashi","year":"1989","unstructured":"Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M, Tamaoki T . UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities J Antibiot 1989 42: 571\u2013576","journal-title":"J Antibiot"},{"key":"BF2401994_CR70","first-page":"1207","volume":"45","author":"CM Seynaeve","year":"1994","unstructured":"Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville EA, Worland PJ . Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue Mol Pharmacol 1994 45: 1207\u20131214","journal-title":"Mol Pharmacol"},{"key":"BF2401994_CR71","first-page":"2081","volume":"53","author":"CM Seynaeve","year":"1993","unstructured":"Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ . Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells Cancer Res 1993 53: 2081\u20132086","journal-title":"Cancer Res"},{"key":"BF2401994_CR72","first-page":"927","volume":"6","author":"Q Wang","year":"1995","unstructured":"Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA . Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2 Cell Growth Differ 1995 6: 927\u2013936","journal-title":"Cell Growth Differ"},{"key":"BF2401994_CR73","first-page":"4888","volume":"51","author":"S Akinaga","year":"1991","unstructured":"Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M . Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models Cancer Res 1991 51: 4888\u20134892","journal-title":"Cancer Res"},{"key":"BF2401994_CR74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00685899","volume":"33","author":"S Akinaga","year":"1994","unstructured":"Akinaga S, Nomura K, Gomi K, Okabe M . Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells Cancer Chemother Pharmacol 1994 33: 273\u2013280","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2401994_CR75","first-page":"1495","volume":"57","author":"T Akiyama","year":"1997","unstructured":"Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S . G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21\/Cip1\/WAF1\/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells Cancer Res 1997 57: 1495\u20131501","journal-title":"Cancer Res"},{"key":"BF2401994_CR76","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00001813-199901000-00009","volume":"10","author":"T Akiyama","year":"1999","unstructured":"Akiyama T, Shimizu M, Okabe M, Tamaoki T, Akinaga S . Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2\/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole (in process citation) Anticancer Drugs 1999 10: 67\u201378","journal-title":"Anticancer Drugs"},{"key":"BF2401994_CR77","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1006\/bbrc.1996.0310","volume":"219","author":"K Kawakami","year":"1996","unstructured":"Kawakami K, Futami H, Takahara J, Yamaguchi K . UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin- dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line Biochem Biophys Res Commun 1996 219: 778\u2013783","journal-title":"Biochem Biophys Res Commun"},{"key":"BF2401994_CR78","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1159\/000227626","volume":"53","author":"E Shimizu","year":"1996","unstructured":"Shimizu E, Zhao MR, Nakanishi H, Yamamoto A, Yoshida S, Takada M, Ogura T, Sone S . Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines Oncology 1996 53: 494\u2013504","journal-title":"Oncology"},{"key":"BF2401994_CR79","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/jnci\/88.14.956","volume":"88","author":"Q Wang","year":"1996","unstructured":"Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor P . UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53 J Natl Cancer Inst 1996 88: 956\u2013965","journal-title":"J Natl Cancer Inst"},{"key":"BF2401994_CR80","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.274.5293.1664","volume":"274","author":"SJ Elledge","year":"1996","unstructured":"Elledge SJ . Cell cycle checkpoints: preventing an identity crisis Science 1996 274: 1664\u20131672","journal-title":"Science"},{"key":"BF2401994_CR81","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.277.5331.1497","volume":"277","author":"Y Sanchez","year":"1997","unstructured":"Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ . Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25 (see comments) Science 1997 277: 1497\u20131501","journal-title":"Science"},{"key":"BF2401994_CR82","doi-asserted-by":"crossref","first-page":"33455","DOI":"10.1074\/jbc.273.50.33455","volume":"273","author":"L Yu","year":"1998","unstructured":"Yu L, Orlandi L, Wang P, Orr M, Senderowicz AM, Sausville EA, Silvestrini Ra, O'Connor P . UCN-01 abrogates G2 arrest through a cdc2-dependent pathway that involves inactivation of the Wee1Hu kinase J Biol Chem 1998 273: 33455\u201333464","journal-title":"J Biol Chem"},{"key":"BF2401994_CR83","first-page":"4375","volume":"59","author":"JN Sarkaria","year":"1999","unstructured":"Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, Abraham RT . Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine Cancer Res 1999 59: 4375\u20134382","journal-title":"Cancer Res"},{"key":"BF2401994_CR84","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1074\/jbc.275.8.5600","volume":"275","author":"PR Graves","year":"2000","unstructured":"Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H . The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01 J Biol Chem 2000 275: 5600\u20135605","journal-title":"J Biol Chem"},{"key":"BF2401994_CR85","first-page":"2108","volume":"60","author":"EC Busby","year":"2000","unstructured":"Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN . The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1 Cancer Res 2000 60: 2108\u20132112","journal-title":"Cancer Res"},{"key":"BF2401994_CR86","first-page":"4029","volume":"57","author":"RG Shao","year":"1997","unstructured":"Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y . Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function Cancer Res 1997 57: 4029\u20134035","journal-title":"Cancer Res"},{"key":"BF2401994_CR87","first-page":"779","volume":"8","author":"RT Bunch","year":"1997","unstructured":"Bunch RT, Eastman A . 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells Cell Growth Differ 1997 8: 779\u2013788","journal-title":"Cell Growth Differ"},{"key":"BF2401994_CR88","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF00685833","volume":"32","author":"S Akinaga","year":"1993","unstructured":"Akinaga S, Nomura K, Gomi K, Okabe M . Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C Cancer Chemother Pharmacol 1993 32: 183\u2013199","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2401994_CR89","first-page":"791","volume":"2","author":"RT Bunch","year":"1996","unstructured":"Bunch RT, Eastman A . Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor Clin Cancer Res 1996 2: 791\u2013797","journal-title":"Clin Cancer Res"},{"key":"BF2401994_CR90","first-page":"2201","volume":"4","author":"CT Hsueh","year":"1998","unstructured":"Hsueh CT, Kelsen D, Schwartz GK . UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner (in process citation) Clin Cancer Res 1998 4: 2201\u20132206","journal-title":"Clin Cancer Res"},{"key":"BF2401994_CR91","first-page":"2089","volume":"3","author":"A Husain","year":"1997","unstructured":"Husain A, Yan XJ, Rosales N, Aghajanian C, Schwartz GK, Spriggs DR . UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II) independent of p53 status Clin Cancer Res 1997 3: 2089\u20132097","journal-title":"Clin Cancer Res"},{"key":"BF2401994_CR92","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3171\/jns.1996.84.6.1024","volume":"84","author":"IF Pollack","year":"1996","unstructured":"Pollack IF, Kawecki S, Lazo JS . Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor J Neurosurg 1996 84: 1024\u20131032","journal-title":"J Neurosurg"},{"key":"BF2401994_CR93","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0360-3016(97)00549-X","volume":"39","author":"E Tsuchida","year":"1997","unstructured":"Tsuchida E, Urano M . The effect of UCN-01 (7-hydroxy-staurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma Int J Radiat Oncol Biol Phys 1997 39: 1153\u20131161","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF2401994_CR94","volume-title":"Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms","author":"AM Senderowicz","year":"1998","unstructured":"Senderowicz AM, Headlee D, Lush R, Bauer K, Figg W, Murgo AS, Arbuck S, Inoue K, Kobashi S, Kuwabara T, Sausville E . Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms 10th National Cancer Institute-European Organization for Research on Treatment of Cancer Symposium Proccedings, Amsterdam, Holland 1998"},{"key":"BF2401994_CR95","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1007\/s002800051080","volume":"42","author":"EA Sausville","year":"1998","unstructured":"Sausville EA, Lush RD, Headlee D, Smith AC, Figg WD, Arbuck SG, Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayashi S . Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models Cancer Chemother Pharmacol 1998 42: (Suppl) S54\u201359","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2401994_CR96","first-page":"3248","volume":"58","author":"E Fuse","year":"1998","unstructured":"Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg W, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara TSK . Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein Cancer Res 1998 58: 3248\u20133253","journal-title":"Cancer Res"},{"key":"BF2401994_CR97","volume-title":"Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. Proc","author":"AM Senderowicz","year":"1999","unstructured":"Senderowicz AM, Headlee D, Lush R, Bauer K, Figg W, Murgo AS, Arbuck S, Inoue K, Kobashi S, Kuwabara T, Sausville E . Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. Proc Thirty-fifth Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA 1999"},{"key":"BF2401994_CR98","first-page":"415","volume":"6","author":"WH Wilson","year":"2000","unstructured":"Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM, Monks A . Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm Clin Cancer Res 2000 6: 415\u2013421","journal-title":"Clin Cancer Res"},{"key":"BF2401994_CR99","unstructured":"Tamura T, Sasaki Y, Minami H, Fujii H, Ito K, Igarashi T, Kamiya Y, Kurata T, Ohtsu T, Onozawa Y, Yamamoto N, Yamamoto N, Watanabe Y, Tanigaara Y, Fuse E, Kuwabara T, Kobayahsi S, Shimada Y . Phase I study of UCN-01 by 3-hour infusion Proceedings of the American Society of Clinical Oncology, Atlanta, GA 1999 p 159"},{"key":"BF2401994_CR100","volume-title":"A phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor","author":"E Dees","year":"2000","unstructured":"Dees E, O'Reilly S, Figg W, Elza-Brown K, Aylesworth C, Carducci M, Byrd J, Grever M, Donehower R . A phase I and pharmacologic study of UCN-01, a protein kinase C inhibitor Proceedings American Society of Clinical Oncology, New Orleans 2000"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2401994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2401994","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2401994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:42:31Z","timestamp":1648762951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2401994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,1]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1,1]]}},"alternative-id":["BF2401994"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2401994","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1,1]]},"assertion":[{"value":"17 August 2000","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2000","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2001","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}